CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

Speciality: Oncology

Description:

Welcome to this exploration of how CDK4/6 inhibitors have reshaped survival outcomes in HR+/HER2- advanced breast cancer based on pivotal clinical trials. Dr. Anju Malhotra discusses landmark studies such as MONALEESA, PALOMA, and MONARCH, which demonstrated significant improvements in overall survival (OS) when these inhibitors were combined with endocrine therapy. 

Key findings include prolonged survival in both first-line and later settings, with some agents showing particular efficacy in high-risk subgroups. Stay tuned until the end to understand how these trial results translate into real-world practice, and don’t miss the upcoming discussion on patient selection strategies. Dr. Anju Malhotra examines real-world evidence, highlighting similarities and disparities with trial data—such as adherence rates, toxicity management, and survival trends in diverse populations. 

Real-world studies reveal that while these drugs maintain efficacy, factors like comorbidities, socioeconomic barriers, and access to care can influence outcomes. Watch until the end for actionable insights on optimizing treatment in routine practice, and join us for the next video addressing CDK4/6 inhibitors in special populations, such as older adults or those with visceral metastases.

See More Webinars @ Hidoc Webinars